Congress is unlikely to codify the recent executive order to lower drug pricing as other US officials negotiate new prices, John Barkett, MBA, of Berkeley Research Group, explains.
John Barkett, MBA
Advertisement
Managing director in Berkeley Research Group's Healthcare Transactions and Strategy practice
Articles by John Barkett, MBA
The immediate impact of the recent executive order aimed at lowering drug prices is likely low, as it may take until 2027 before actions detailed in the order can be enacted.
The executive order that President Donald Trump signed to lower drug prices could come under legal challenges by the drug industry.
The executive order signed on May 12 has some differences from a previous executive order originally signed by the Trump administration in 2020.
The new executive order contains multiple provisions if pharmaceutical companies do not offer "most-favored nation" pricing on medication.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Newly Unveiled ACA Premiums Show 26% Average Increase Before Subsidy Expiration
2
FDA Guidance to Remove One of the Largest Barriers to Biosimilar Development
3
Boosting RSV Vaccination in Older Adults Could Save Thousands
4
Cancer Care in Transition: Navigating Breakthrough Therapies Amid Economic Strain
5
